Az emlőrák endokrin kezelésének kutatási távlatai

Magyar Onkologia

Volumn 47, Issue 2, 2003, Pages 133-140

  Sándor, Eckhardt ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ENZYME INHIBITOR; ESTRADIOL; EXEMESTANE; FULVESTRANT; LETROZOLE; NITRILE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TOREMIFENE; TRIAZOLE DERIVATIVE;

BREAST TUMOR; FEMALE; HUMAN; REVIEW;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; NITRILES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TOREMIFENE; TRIAZOLES;

EID: 0642377618     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev 2:101-112, 2002
2. Adem C, Reynolds C, Soderberg CL, et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97:1-11, 2003
3. The ATAC Trialist's Group. Anastrozol alone or in combination with tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
4. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2:104-107, 1896
5. Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347:886-894, 2002
6. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene, 4 year results from the MORE trial. Breast Cancer Res Treat 65:125-134, 2001
7. Cho M, Chen S. Suppression of aromatase by phytochemicals. Proc Am Assoc Cancer Res 43:1078, 2002
8. Clamp A, Danson S, Clemons M. Hormonal risk factors for breast cancer: identifications, chemoprevention and other intervention strategies. Lancet Oncol 2:611-619, 2002
9. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Cancer 73:643-651, 1994
10. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 344:276-285, 2002
11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713-1727, 1996
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: a collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059, 1997
13. Collins P, Webb C. Estrogen hits the surface. Nat Med 5:1130-1131, 1999
14. Csókay B, Udvarhelyi N, Sulyok Z, et al. High frequency of germline BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 59:995-998, 1999
15. Cummings SR, Eckert S, Krueger KA, et al. The effects of raloxifene on the risk of breast cancer in postmenopausal women: results from the Multiple Outcomes of Raloxifene Evaluation randomized trial. JAMA 281:2189-2197, 1999
16. Dank M. The role of Aromasin in the hormonal therapy of breast cancer. Pathol Oncol Res 8:87-92, 2002
17. Dancsó J, Cseh I, Fülöp V, et al. Az ösztrogén jelátvitel és a szelektív ösztrogén modulácó (SERM). Magyar No{double acute}orvosok Lapja 63:113-118, 2000
18. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overwiev of the randomised trials. Lancet 351:1451-1467, 1998
19. Ellis M, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant therapy than tamoxifen for ErbB1-and/or ErbB2-positive estrogen-receptor positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
20. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82:4258-4265, 1999
21. Fanti V, Stamp G, Andrew A, et al. Mice lacking cyclin D are small and show defect in eye and mammary gland development. Genes Dev 9:2364-2372, 1995
22. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
23. Feigelson HS, McKean-Cowdin R, Pike MC, et al. Cytochrome P450c alpha gene (CYP) polymorphism predicts use of hormone replacement therapy. Cancer Res 59:3908-3910, 1999
24. Fornander T, Rutquist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117-120, 1989
25. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886, 1989
26. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894, 2001
27. Gottardis MM, Robinson SP, Satyaswaroop PG, et al. Contrasting actions of tamoxifen on endometrial and breast cancer growth in the athymic mouse. Cancer Res 48:812-815, 1988
28. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to verb-A. Nature 320:134-139, 1986
29. Gronemeyer H. Transcription activation by estrogen and progesteron receptors. Annu Rev Genet 25:89-123, 1991
30. Gruber DM, Huber JC. Tissue specificity: the clinical importance of steroid metabolites in hormone replacement therapy. Maturitas 37:151-157, 2001
31. Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med 346:340-352, 2002
32. Hayes DF, Danzil JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2564, 1995
33. Henderson BE, Ross RK, Judd HL, et al. Do regular ovulatory cycles increase cancer risk? Cancer 56:1206-1208, 1985
34. Holmes MD, Hunter DJ, Colditz GA, et al. Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA 281:914-920, 1999
35. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as Anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396-3403, 2002
36. Hulka BS. Epidemiologic analysis of breast and gynecologic cancers. Prog Clin Biol Res 396:17-29, 1997
37. Kallen CB, Billheimer JT, Summers SA, et al. Steroidogenic acute regulatory protein (StAR) is a sterol transfer protein. J Biol Chem 273:2685-2688, 1998
38. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestan is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. J Clin Oncol 18:1399-1411, 2000
39. Kauffman RF, Bryant HU. Selective estrogen receptor modulators. Drug News Perspect 8:531-539, 1995
40. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5309, 1996
41. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863-870, 1997
42. Kuiper GG, Lemmen J, Carlsson B, et al. Interactions of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:4252-4263, 1998
43. Labrie F, Labrie C, Belanger, et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Med Biol 69:51-84, 1999
44. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 54:40-54, 2000
45. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestan in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18:2234-2244, 2000
46. Madigan MP, Ziegler RG, Benichou J, et al. Proportion of breast cancer cases in the United States explained by well established risk factors. J Natl Cancer Inst 87:1681-1685,1995
47. Marton I, Kisfalvi I. Az oszteoporózis hormonpótló és SERM kezelésének onkológiai vonatkozásai. MOTESZ Magazin 10:25-31, 2002
48. Mc Mahon C, Sutipongchai T, Di Renzo J, et al. P/CAF association with cyclin D1 potentiates the activation of estrogen receptor. Proc Natl Acad Sci USA 96:5382-5387, 1999
49. Moskovits K. Változások az emlo{double acute}rák hormonterápiájában. Lege Artis Medicinae 12:481-487, 2002
50. Mouridsen HT, Gerschanovitch M, Sun Y, et al. Superior efficacy of letrozol versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
51. Munster PN, Buzdar A, Dhingra, et al. Phase I trial of third generation selective estrogen receptor modulator, LY 353381.HCL (Arzoxifene) in metastatic breast cancer. J Clin Oncol 19:2002-2009, 2001
52. Nagykálnai T. Szelektív ösztrogénreceptor- modulátorok (SERM-ek) a gyakorlatban. Magyar Onkológia 46:165-175, 2002
53. Newcomb PA, Longnecker MP, Storer BE, et al. Recent oral contraceptive use and risk of breast cancer. Cancer Causes Control 7:525-532, 1996
54. Oláh E. Az örökletes emlo{double acute}rákok genetikája és molekuláris diagnosztikája. In: Az emlo{double acute}rák aktuális kérdései. Eds: Tóth J, Péter I. Springer kiadó, Budapest, 2001, pp. 115-126
55. Oláh E. Molekuláris Onkogenetika, Onkogenomika. Magyar Onkológia 46:287-290, 2002
56. O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol 3:207-214, 2002
57. Péter I, Számel I, Rhodes A, et al. A szteroidhormon- receptor immunhisztokémiai meghatározásának gyakorlata és klinikai jelento{double acute}sége. In: Az emlo{double acute}rák aktuális kérdései. Eds: Tóth J, Péter I. Springer kiadó, Budapest, 2002, pp. 148-163
58. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosin kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995
59. Richards JS. Hormonal control of gene expression in the ovary. Endocr Rev 15:725-751, 1994
60. Robertson JFR, Nicholson RI, Anderson E, et al. The antitumor effects of single dose long acting Faslodex (ICI 182780) compared with tamoxifen in postmenopausal primary breast cancer patients treated before surgery. Breast Cancer Res Treat 59:99, 2000
61. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328-332, 2000
62. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485-491, 2000
63. Shao D, Lazar MA. Modulating nuclear receptor function: may the phos be with you. J Clin Invest 103: 1617-1618, 1999
64. Siegelman-Danieli N, Buetow KH. Constitutional genetic variations at the human aromatase gene (CYP 19) and breast cancer risk. Br J Cancer 79:456-463, 1999
65. Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 142:4589-4594, 2001
66. Stenbygaard LE, Herrstedt J, Thomsen J, et al. Toremifene and tamoxifen in advanced breast cancer-a double-blind cross-over study. Breast Cancer Res Treat 25:67-73, 1993
67. Smith C. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 58:627-632, 1998
68. Számel I. A szteroidhormon-receptor meghatározá sának gyakorlata és klinikai jelento{double acute}sége. In: Az emlo{double acute}rák aktuális kérdései. Eds: Tóth J, Péter I. Springer kiadó, Budapest, 2002, pp. 139-147
69. Takimoto GS, Graham JD, Jackson TA, et al. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol 69:45-50, 1999
70. Tang M, Abplanalp W, Subbiah MT. Association of estrogens with human plasma lipoproteins: studies using estradiol-17beta and its hydrophobic derivative. J Lab Clin Med 129:447-452, 1997
71. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 76:401-405, 1997
72. Thomas HV, Key TJ, Allen DS, et al. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 89:396-398, 1997
73. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87:190-197, 1995
74. Tóth J, Péter I. (szerk). Az emlo{double acute}rák aktuális kérdései. Springer Tudományos Kiadó, Budapest, 2002, pp. 1-249
75. Tryggvadottir L, Tullinius H, Gudmundsdottir GB. Oral contraceptive use at a young age and the risk of breast cancer: an Icelandic, population based cohort study of the effect of birthyear. Br J Cancer 75:139-143, 1997
76. Ursin G, Henderson BE, Haile RW, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 57:3678-3681, 1997
77. Van der Looij, Szabó C, Besznyák I, et al. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 86:737-740, 2000
78. Vogel CI, Shemano I, Schoenfelder J, et al. Multicenter phase II trial of toremifene in tamoxifen-resistant advanced breast cancer. J Clin Oncol 11:345-351, 1993
79. Wakeling AE, Bowler J. Steroidal pure antioestrogens. J Endocrinol 112:R7-10, 1987
80. Weigel NI. Steroid hormone receptors and their regulation by phoshorylation. Biochem J 319:657-667, 1996
81. Willson TM, Henke BR, Momtahen TM, et al. 3-[4-(1,2-diphenylbut-1-enyl] phenyl/acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 37:1550-1552, 1994
82. Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. In: Cancer: Principles and Practice of Oncology (6th edition) Eds: De Vita VT, Hellman S, Rosenberg SA. Lippincott, Williams and Wilkins, Philadelphia, 2001, pp. 1651-1717
83. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
84. Zwijsen RM, Buckle RS, Hijmans EM, et al. Ligandindependent recruitment of steroid coactivators to estrogen receptor by cyclin D1. Genes Dev 12:3488-3498, 1998